Immunitybio, Inc.

This phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to…

This early-phase trial tests whether adding three experimental drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are borderline removable or locally advanced. About 30 adults with pancreatic cancer…

This study tests whether adding an experimental drug called nogapendekin alfa inbakicept (NAI) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 494 adults with stage IV lung cancer …

This study tests an experimental drug (NAI) added to usual care for critically ill adults with sepsis who have persistently low levels of a key immune cell (lymphocytes). The goal is to see if the drug can help the immune system recover and lower the risk of death within 28 days.…

This study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults …